How long will I need to take Kisunla?
The length of treatment with Kisunla (donanemab-azbt) for Alzheimer's disease is different for each person. The recommended dose is 700 mg given by intravenous infusion every 4 weeks for three doses, and then 1,400 mg every 4 weeks.
Your healthcare provider will monitor how well the medication is working through PET scans of your brain. Once they see Kisunla has reduced amyloid plaques to low levels, they may consider stopping the medication.
In clinical trials, 69% of people taking Kisunla had amyloid levels low enough to stop treatment. Keep in mind that after stopping Kisunla it is possible for amyloid levels to go back up. Research is ongoing to determine whether additional doses of Kisunla might be needed if this happens.
This is not all the information you need to know about Kisunla (donanemab-azbt) for safe and effective use. Review the full Kisunla (donanemab-azbt) information, and discuss this and any questions you have with your doctor or other health care provider.
References
Kisunla [package insert]. Updated July 2024. Eli Lilly and Company. Accessed September 11, 2024 at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=190352d4-ef62-4679-b4fa-e846e2766afa
Read next
How do I decide between Leqembi and Kisunla?
Leqembi (lecanemab-irmb) and Kisunla (donanemab-azbt) are two injectable treatments for Alzheimer’s disease. While both medications work by reducing amyloid plaques in the brain, there are some differences to consider when deciding between the two. These include effectiveness, side effects, and cost. Continue reading
Will insurance cover Kisunla treatment?
Kisunla treatment typically requires a prior authorization approval from your commercial insurance company before they will pay for it. Medicare Part B may pay for Kisunla and brain imaging scans if you are eligible, but you must first meet your yearly deductible and then pay coinsurance costs, which are usually 20%. Continue reading
How well does Kisunla work?
In studies, treatment with Kisunla significantly slowed Alzheimer's disease clinical decline when compared to a group who received a placebo. People with the least advanced disease experienced the strongest outcomes, with a 35% slowing of decline on the iADRS score, which measures memory, thinking, and daily functioning. Continue reading
Related medical questions
- How quickly does Kisunla start working?
- Can Kisunla be used with other Alzheimer's drugs?
- Can Aricept be stopped abruptly?
- What is Quercetin and what are its health benefits?
- What are 7 key Aricept side effects to watch out for?
- When is the best time to take Aricept (donepezil)?
- How long does it take for Aricept to work?
- What is the controversy surrounding Leqembi?
- How does Aricept work?
- What's the mechanism of action for Leqembi (lecanemab-irmb)?
- What are 4 key Namenda side effects to watch out for?
- How effective is Leqembi in delaying Alzheimer's disease?
- How does Namenda work?
- Is Leqembi eligible for Medicare or insurance coverage?
- Is Razadyne (galantamine) used to treat Alzheimer’s?
- What are the current medications for Alzheimer's disease?
- Caring for a Senior with Dementia
Drug information
- Kisunla Information for Consumers
- Kisunla prescribing info & package insert (for Health Professionals)
- Side Effects of Kisunla (detailed)
Related support groups
- Kisunla (6 questions, 3 members)
- Alzheimer's Disease (35 questions, 98 members)